Aim: To determine the effect of levothyroxine (L-T4) therapy on the recurrence rate of nodular disease in patients previously treated with lobectomy for benign nodular goiter. Methods: Two hundred and thirty-tree patients (38 males, 195 females; age 49.9±13.1 yr) with no post-surgical evidence of nodular disease in the remnant, were followed-up yearly with serum TSH and ultrasound (US). Nodular recurrence was defined as a lesion of at least 5 mm at US. Patients were divided in 2 groups based on whether or not they had been treated with L-T4 after surgery: Group 1 (45 patients) who did not receive any L-T4, and Group 2 (188 patients) treated with L-T4. Group 2 was further subdivided in Group 2a (123 patients) receiving L-T4 substitutive therapy (TSH≥0.5 and ≤3 mUI/l) and Group 2b (65 patients) receiving L-T4 at TSH-suppressive dose (TSH4 therapy may prevent recurrence of nodular disease. TSH suppression may not be required for prevention of recurrence in the remnant thyroid tissue.
|Number of pages||5|
|Journal||Journal of Endocrinological Investigation|
|Publication status||Published - Apr 2009|
- Nodular recurrence
- TSH suppression
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism